(S)-4-Fluoro-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline hydrochloride dihydrate is a complex heterocyclic compound featuring an isoquinoline core substituted with a fluoro group and a sulfonamide-linked (S)-2-methyl-1,4-diazepane moiety. It is supplied as a hydrochloride salt dihydrate. This compound is a key intermediate in the synthesis of GDC-0084 (Paxalisib), a potent, brain-penetrant, dual inhibitor of PI3K and mTOR signaling pathways. GDC-0084 is an investigational small molecule drug developed for the treatment of glioblastoma and other solid tumors. The specific stereochemistry and functional groups of this intermediate are critical for the final drug's biological activity and pharmacokinetic properties. As a specialized building block in oncology drug development, its primary use is confined to pharmaceutical research and manufacturing processes for targeted cancer therapies. Handling requires standard laboratory safety precautions for potent bioactive intermediates.